EVAX
Evaxion Biotech A/S·Healthcare
4.04
1.703%(−0.07)
Market ClosedLast Updated: — ET
52W L: $1.2552W H: $12.15
EVAX NEWS
defenseworld.net
Apr 3
Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) PT at $11.00
Shares of Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The
globenewswire.com
Mar 30
Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress
COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has in collaboration with the Gates Foundation developed novel and potentially superior concepts for design of vaccines to combat polio. These concepts, and the underlying research, will be presented at the World Vaccine Congress taking place in Washington D.C. from March 31 to April 2, 2026.
globenewswire.com
Mar 19
Notice to convene Evaxion's Annual General Meeting
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET.
defenseworld.net
Mar 9
Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives $11.75 Average Target Price from Analysts
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation
seekingalpha.com
Mar 6
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript
Evaxion A/S (EVAX) Q4 2025 Earnings Call Transcript
defenseworld.net
Mar 6
Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Up 20.9% in February
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 82,140 shares, a growth of 20.9% from the January 29th total of 67,935 shares. Based on an average trading volume of
